Effectiveness of the WearME System for COPD Severity and Respiratory Function

COPD is the third leading cause of death worldwide, with over 3 million deaths and an estimated total cost of $52 billion in the U.S. alone. This project, in collaboration with the Johns Hopkins Clinical Research Network (JHCRN), aims to provide technological innovation access to underserved patients in low-income, rural, and diverse ethnicities in the Mid-Atlantic region.

The symptoms of COPD include dyspnea (shortness of breath), coughing and the production of sputum. Recent data shows that the 30-day readmission rate of COPD patients is approaching 23%, creating a huge burden on the health care system. Exacerbations can commonly be treated in the home if detected early, so early recognition of symptoms signaling an impending COPD exacerbation may reduce readmission and associated healthcare costs. The standard adjuncts used to assess lung function (e.g., spirometry, plethysmography, CT scan) require oversight by medical experts, are time consuming, and do not allow for continuous and remote patient monitoring of an acute exacerbation. Early recognition of deteriorating patient's lung function will enable timely intervention and help manage changes in COPD severity.

2\. EFFECTIVENESS STUDY OVERVIEW

In this study, the WearME-Basic functionality will be validated while using the same hardware needed for the WearME-Basic app. Since the hardware collects all data needed to supply either the Basic or Pro app, the investigators will also gain insights on both the Basic and Pro simultaneously during this study.

This study will assess the effectiveness of the WearME-Pro system in monitoring COPD patients by measuring the accuracy and reliability of the system for forced expiratory volume (FEV₁), forced vital capacity (FVC), respiratory rate, heart rate, I:E ratio, spinal range of motion (ROM), and activity levels. Up to 128 COPD participants will be recruited from the LASARRUS outpatient clinic, Johns Hopkins and TidalHealth hospitals, and stratified into four groups based on the GOLD standard for severity stratification. Participants will be asked to wear the WearME system during a data collection period of 145 minutes.

The primary outcome measure will be the Bland-Altman LOA between the FEV1/FVC measurements of WearME-Pro FEV1/FVC prediction (recorded within the WearME-Basic app but not displayed to users) and the gold standard devices. Secondary outcomes include the validation of the WearME-Basic system for FDA submission by evaluating its accuracy in measuring respiration rate, heart rate, I:E ratio, and ROM compared to gold standard reference devices, and correlation of I:E measured by the WearME device to FEV1/FVC measured by spirometry.

We will use standard medical devices as reference devices for comparison with the WearME systems outputs. The specific devices used for spirometry, capnography, heart rate monitoring, and range of motion measurement will be appropriate, FDA-cleared devices commonly used in clinical practice.

Details of the specific device models and their usage will be documented in the Manual of Procedures (MOP). The sponsor will provide all necessary reference devices to the study sites, including the spirometers, capnographs, and other equipment required for the study.

• Accuracy of WearME-Basic in measuring Respiration Rate [Time frame: Within 6 months of study start.]
• Accuracy of WearME-Basic in measuring I:E ratio [Time frame: Within 6 months of study start.]
• Accuracy of WearME-Basic in measuring Heart Rate [Time frame: Within 6 months of study start.]
• Accuracy of WearME-Basic in measuring ROM [Time frame: Within 6 months of study start.]